An explosive study on add-on effects of ribavirin in sofosbuir and ledipasvir combination therapy for patients who failed to daclatasvir and asunaprevir combination therapy

INTERVENTION: RBV add‐on for 12 weeks CONDITION: Patients with chronic HCV infection, who failed to DCV/ASV therapy PRIMARY OUTCOME: To investigate the sustained virologic response (SVR) rate at follow‐up Week 12 SECONDARY OUTCOME: Effects of HCV NS5A/B mutations as viral factors on virologic response; 2) Rate of emergence of drug‐resistant variants; 3) Presence or absence of a reversal of liver fibrosis; 4) Presence or absence of an improvement in AFP levels; 5) Incidence of AEs INCLUSION CRITERIA: Patients (1) with the target disease who (2) satisfy all the inclusion criteria and (3) meet none of the exclusion criteria are eligible for the study. (1) Subjects Patients with a chronic HCV infection and compensated cirrhosis who failed to DCV/ASV combination therapy (2) Inclusion criteria [1] Patients who are 20 years of age or older at the time of informed consent [2] Patients who have been fully informed and have provided written informed consent to participate in this study prior to study initiation [3] Patients with a chronic HCV genotype 2 infection and compensated cirrhosis who do not meet any of the following exclusion criteria